Expansion of the healthcare business network through the acquisition of DHC
First written in FY2023-Q3. 1 of 3 entries say "Achieved", first in FY2023. Latest entry: FY2024-Q3.
No other company in this theme has enough history to compare yet.
- FY2024-Q3AdvancedAnnual report
「The purchase price allocation was completed during the third quarter of the current consolidated fiscal year. As a result, the fair values assigned to DHC's assets and liabilities were as follows.」
For the acquisition of DHC, the purchase price allocation was completed in the third quarter following the creation of a wholly owned subsidiary on 31 January 2023. Goodwill of ¥94,324 million and identifiable intangible assets of ¥104,910 million at the acquisition date were finalized. - FY2023AchievedAnnual report
「To expand the network of the Group's healthcare business, on 11 November 2022 the Company entered into a share transfer agreement with Yoshida Yoshiaki (吉田 嘉明), a major shareholder of DHC Co., Ltd. (hereinafter, "DHC"), and reached a basic agreement under which the Company would acquire shares of DHC. On 31 January 2023, the business combination date, the Company acquired all issued shares and DHC became the Company's wholly owned subsidiary. The total acquisition price was ¥300,000 million, payable in cash.」
For DHC, the Company acquired all issued shares on 31 January 2023 and completed the process of making it a wholly owned subsidiary. The total acquisition price was ¥300 billion. - FY2023-Q3First statedAnnual report
「To expand the network of the Group's healthcare business, on 11 November 2022 the Company entered into a share transfer agreement with Yoshida Yoshiaki (吉田 嘉明), a major shareholder of DHC Co., Ltd. (hereinafter, "DHC"), and reached a basic agreement under which the Company would acquire shares of DHC. On 31 January 2023, the Company acquired 91.1% of DHC's total issued shares and made it a consolidated subsidiary. The Company aims to acquire all issued shares. The total acquisition cost is expected to be approximately ¥300 billion, payable in cash.」
To expand its healthcare business network, the Company acquired 91.1% of DHC's shares on 31 January 2023 and made DHC a consolidated subsidiary. The Company aims to acquire all issued shares, with the total acquisition cost expected to be approximately ¥300 billion.